Bio Innovation Conference | 2021 Agenda
Presented by Maryland Life Sciences, a division of the Maryland Tech Council, the Bio Innovation Conference is driving the future of life sciences in Maryland. This conference provides a forum for professionals from industry, academia and government to discuss trends and insight into Maryland’s burgeoning life sciences industry and topics related to funding, structuring, commercialization and government relations.
Maryland Life Sciences Bio Innovation Conference, Bio Innovation Conference, Maryland, life sciences, biotechnology, Maryland Tech Council, bio, innovation, conference, Maryland Life Sciences, Bio Innovation Conference, vaccines, gene therapy, networking, Washington DC, DMV, Biohealth, biohealth capital region, sciences, entrepreneurship, entrepreneur, startup, Maryland Life Sciences Bio Innovation Conference, Maryland Tech Council Conference, annual conference
page-template,page-template-full_width,page-template-full_width-php,page,page-id-20103,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive

2021 Agenda

Join Us on October 4-6 • Bethesda Country Club + Virtual

Day 1  |  October 4, 2021


7:00 am – 8:00 am Registration Open – Breakfast and Networking
9:00 am – 5:00 pm Virtual Exhibit Hall Open
8:00 am – 8:45 am Welcome

Brad Stewart, Senior Vice President of Business Development, Montgomery County Economic Development Corporation

Steven Walker, Senior Director, Global Marketing – Early Portfolio Strategy, GSK

Opening Remarks and State of the State

Martin Rosendale, Chief Executive Officer, Maryland Life Sciences

Kelly Schulz, Secretary, Maryland Department of Commerce

8:45 am – 9:45 am Fireside Chat

Gary Disbrow, PhD, Director, Deputy Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

Sally Allain, Head, Johnson & Johnson Innovation – JLABS @ Washington, DC

9:45 am – 10:00 am Break
10:00 am – 10:50 am Keynote Speaker
11:00  am – 11:50  am Disruptive Technology Innovation and Vaccine Development

mRNA and viral based vaccines have led the way in rapidly addressing the Covid-19 pandemic. Expert panelists from companies leading the development of these disruptive technologies will discuss their impact, what’s next for these technologies and what other disruptive technologies may be around the corner.

Brad Stewart, Senior Vice President of Business Development, Montgomery County Economic Development Corporation

Bill Enright, Chief Executive Officer, Vaccitech

Mary Moran, MD, Viral Vaccines Medical & Scientific Affairs Lead, Pfizer

Robert van den Berg, PhD, MBA, Head of the Data Sciences & Computational Vaccinology, GSK

12:00 pm – 1:00 pm Networking Lunch
1:00 pm – 1:50 pm Health Equity and Vaccine Confidence

Everyone should have a fair and just opportunity to be healthy. Biomedical professionals and health policy and equity leaders will come together to provide straight talk and discuss the obstacles with trying to obtain fair health care, ensuring diversity in clinical trials, overcoming issues of mistrust, and addressing vaccine hesitancy.

Dr. Lisa Dunkle, Vice President, Clinical Development Global Medical Lead, Novavax

Matthew Hepburn, Director, COVID Vaccine Development, HHS-DoD Countermeasures Acceleration Group

Stephen Thomas, Professor, Health Policy & Management, Director, Maryland Center for Health Equity, University of Maryland College Park

2:00 pm – 2:50 pm Innovation in Clinical TrialsFireside Chat  |  Scaling up in the “New Normal”

Pre and post pandemic, a start-up life science company’s fundraising journey continues to be challenging.  In the candid fire side chat, you will hear from Marty Rosendale and Christopher Austin as they share their knowledge about capital raising in Maryland, challenges entrepreneurs face, especially during the pandemic and how they were overcome, how to identify investors and unique fundraising opportunities and what the landscape looks like for the future.

Christopher Austin, MD, Chief Executive Officer-Partner, Flagship Pioneering

Martin Rosendale, Chief Executive Officer, Maryland Life Sciences

3:00 pm – 3:50 pm Biotech Careers: Everyone Can Take Part in Shaping the Future

The life sciences industry in Maryland and the larger BioHealth Capital Region is experiencing significant growth, providing opportunities for local talent to enter the workforce at multiple entry points.  The region has a robust supply of talent that can support the growing demand of the local biopharmaceutical industry; however, there is a need to stimulate stronger interest in industry careers by deliberately engaging diverse talent where they are and delivering a clear value proposition.  Members of the joint task force organized by the Maryland Life Sciences Advisory Board and the Maryland Tech Council will discuss ongoing efforts that seek to improve this connectivity and share successful models of building robust talent pipelines that can support the growth of the regional innovation ecosystem.

Ulyana Desiderio, PhD, Director, BioHealth and Life Sciences, Department of Commerce 

Michael Nestor, PhD, Scientific Engagement Lead, Johnson & Johnson Innovation – JLABS @ Washington D.C.

KaShauna Rohlehr, MBA, PMP, Associate Director – Alliance, Program and Project Management, GlaxoSmithKline

Joe Sanchez, PhD, MBA, Director, Science Engagement & STEM Programming, R&D North America, AstraZeneca

Brian Stamper, Senior Director of Manufacturing, Kite Pharma

4:00 pm – 5:30 pm Cocktail Reception

Day 2  |  October 5, 2021

7:00 am – 8:00 am Registration Open – Breakfast and Networking
9:00 am – 5:00 pm Virtual Exhibit Hall Open
8:00 am – 9:00 am Welcome and Keynote Speaker

Dr. David Agus, Chief Executive Officer, Ellison Institute, physician, author, CBS Medical Contributor

Martin Rosendale, Chief Executive Officer, Maryland Life Sciences

9:00 am – 9:50 am Engineered Cell Therapies: Increasingly Complex Product Development

The development of next generation engineered cell therapies has expanded into novel cell types and are designed with increasingly sophisticated engineering approaches. In this session, we will hear from two companies developing  innovative approaches for novel cell therapeutics for the treatment of a growing list of intractable diseases.  The presentations will be followed by a short Q/A session with the panelists. 

Doug Doerfler, President and Chief Executive Officer, MaxCyte

Sarah Meeks, Senior Vice President, Business Development, MaxCyte

Mike Klichinsky, Co-Founder Senior Vice President, Research, Carisma Therapeutics

Michael Singer MD, PhD, Chief Scientific Officer, Cartesian Therapeutics

10:00  am – 10:50  am Cell and Gene Therapy: CMC and Manufacturing Hurdles and Solutions

Manufacturing of cell and gene therapy is the bottleneck for availing this line of innovative therapies to clinical trials and patients. In this panel, we invited the world experts in cell and gene therapy to address Chemistry, Manufacturing and Controls (CMC) aspects of cGMP manufacturing of cell and gene therapy. The topics include quality by design, scaleup, process control, and product characterization and release. The goal for the panel is to share insights on how to design CGT product and production processes to allow for quality and speedy release.

Jeffrey Hung, General Manager, Vigene Biosciences

Matthew Hewitt, B.A, PhD, Senior Director, Scientific Solutions, Cell and Gene Therapy, Charles River Labs

David Anderson, Senior Director, Quality Site Head, Kite Pharma

 Jon Rowley, Chief Product Officer, RoosterBio

11:00 am – 11:50 am Cell and Gene Therapy: Beyond Oncology

The Beyond Oncology panel will discuss applications of cell therapy beyond treatment of advanced cancers. Specific examples will include use of cell & gene therapy for treatment of autoimmune disorders such as myasthenia gravis, respiratory diseases such as ARDS and COVID-19, and rare genetic disorders such as XMEN disease. Ex-vivo cell modification strategies will be compared between different approaches and disease indications. Potential benefits of these novel approaches will be weighed against treatment risks and costs.

Murat Kalayoglu, M.D., PhD, President, Cartesian Therapeutics

Suk See DeRavin, Clinician, Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH

Dr. Bruce Levy, Chief of Pulmonary and Critical Care Division, Brigham and Women’s Hospital, Harvard Medical School

Dr. Tahseen Mozaffar, Professor, Neurology and Laboratory Medicine, University of California, Irvine

12:00 pm – 1:00 pm Lunch Break
1:00 pm – 1:50 pm Fireside Chat  |  Bringing Hope to Patients—Advanced Manufacturing at Kite

Jim Jackson, Vice President, Manufacturing, Kite Pharma

Nicole Wood, Senior Regional Director, State Advocacy, PhRMA

2:00 pm – 2:50 pm Biomanufacturing: Buy it or Build it (Pros and cons of insourcing vs. outsourcing)

With the explosion of biomanufacturing needs being driven by a rapid expansion of funding and life sciences innovations and successes, a critical question persists whether the industry can meet these current and future demands. Will the manufacturing capacity be there to deliver on the promise of great, innovative science? Should needed biomanufacturing be performed in-house with complete control of timelines, budgets and processes or out-source to companies that have the existing facilities, equipment, track record and capability, but may be delayed in offering a slot? If in-house work is on the table, companies have to consider building a new facility and organizational structure, shouldering high capital costs, and managing the long timelines associated with validation and possibly repurposing the equipment if their needs change.

Ben Skowronski, Senior Director, Maryland Office Lead, Associate, CRB Group

Craig Malzahn, Vice President, Technical Operations, RegenxBio

Harish Santhanum, Senior Director, Manufacturing Science and Technology, Kite Pharma

Thomas VanCott, PhD, Global Head of Product Development, Cell and Gene Therapy, Catalent Biologics

3:00 pm – 3:50 pm Revolution in Biomanufacturing

One of the biggest drivers of biomanufacturing has been the rapid advances in vaccine and cell therapy and their production is undergoing a record transformation. These new technologies will serve as the cornerstone for biomanufacturing facilities of the future. Our panel discussion on Revolutions in Biomanufacturing will highlight the next generation ecosystem of processes, data acquisition, analysis and software automation and how they are used to bring medicines to market faster.

Martin Rosendale, Chief Executive Officer, Maryland Life Sciences

Catherine Hanley, Vice President and interim CDMO Business Unit Head, Emergent Biosolutions

Peter Olagunju, Chief Technical Officer, TCR2 Therapeutics

Nicholas Ostrout, PhD, Global Head of Commercial Development – Personalized Medicine, Lonza

3:50 pm – 4:00 pm Closing Remarks

Martin Rosendale, Chief Executive Officer, Maryland Life Sciences

Brad Stewart, Senior Vice President of Business Development, Montgomery County Economic Development Corporation

Steven Walker, Senior Director, Global Marketing – Early Portfolio Strategy, GSK

Day 3  |  October 6, 2021

7:00 am – 7:00 pm BIO One-on-One Partnering (available 24 hours for scheduling)